Fernando Salazar-De La Garza
Monterrey, NLE, Mexico
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Romiplostim, low-dose rituximab and high-dose dexamethasone for newly diagnosed immune thrombocytopenia: A pilot study.
Journal: British journal of haematology
Published: October 06, 2024
Case series: CYP Inhibition and low dose ibrutinib for steroid-refractory chronic graft-versus-host disease.
Journal: British journal of haematology
Published: January 19, 2023
Vinblastine as a bridge to 7 + 3 in acute myeloid leukaemia.
Journal: Annals of hematology
Published: November 03, 2022
Cytochrome P450 inhibition to decrease dosage and costs of venetoclax and ibrutinib: A proof-of-concept case study.
Journal: British journal of clinical pharmacology
Published: August 10, 2022
Orbital myeloid sarcoma treated with low-dose venetoclax and a potent cytochrome P450 inhibitor.
Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: June 24, 2022
Oseltamivir as rescue therapy for persistent, chronic, or refractory immune thrombocytopenia: a case series and review of the literature.
Journal: Journal of thrombosis and thrombolysis
Published: March 31, 2022
Comparison of the effectiveness of hematopoietic cell mobilization with chemotherapy and filgrastim versus filgrastim alone for autologous transplant in patients with lymphoma.
Journal: Gaceta medica de Mexico
Published: October 30, 2016
More about low-dose rituximab and plasma exchange as front-line therapy for patients with thrombotic thrombocytopenic purpura.
Journal: Hematology (Amsterdam, Netherlands)
Published: February 25, 2016
Showing 1-10 of 10
Last Updated: 09/26/2026